NASDAQ: AXNX | Healthcare / Medical Devices & Instruments / USA |
51.20 | +0.3450 | +0.68% | Vol 94.24K | 1Y Perf -12.27% |
Jun 8th, 2023 11:41 DELAYED |
BID | 51.15 | ASK | 51.24 | ||
Open | 50.67 | Previous Close | 50.85 | ||
Pre-Market | 49.92 | After-Market | - | ||
-0.93 -1.83% | - - |
Target Price | 82.67 | Analyst Rating | Moderate Buy 1.55 | |
Potential % | 61.99 | Finscreener Ranking | ★★★★★ 58.65 | |
Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | ★★★★ 55.49 | |
Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | ★★★★ 58.41 | |
Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | — - | |
Price Range Ratio 52W % | 13.87 | Earnings Rating | Strong Buy | |
Market Cap | 2.58B | Earnings Date | 1st May 2023 | |
Alpha | 0.03 | Standard Deviation | 0.17 | |
Beta | 0.40 |
Today's Price Range 50.5951.33 | 52W Range 46.5779.92 |
Summary:
Neutral
Technical Indicators: | Neutral |
Moving Averages: | Sell |
Performance | |||
---|---|---|---|
1 Week | 3.12% | ||
1 Month | -7.61% | ||
3 Months | -6.04% | ||
6 Months | -22.83% | ||
1 Year | -12.27% | ||
3 Years | 29.59% | ||
5 Years | - | ||
10 Years | - |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | -28.14 | |||
ROE last 12 Months | -15.66 | |||
ROA (5Y Avg) | -8.86 | |||
ROA last 12 Months | -13.64 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -14.09 | |||
Return on invested Capital Q | -3.15 | |||
Return on invested Capital Y | -3.08 | |||
Assets Turnover | 0.30 | |||
Receivables Turnover | 6.10 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-36.40 | ||||
5.38 | ||||
14.51 | ||||
- | ||||
-367.00 | ||||
-0.28 | ||||
7.76 | ||||
11.09 | ||||
2.61B | ||||
Forward PE | -1 209.75 | |||
PEG | - |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
6.40 | ||||
7.40 | ||||
0.01 | ||||
0.02 | ||||
-26.40 | ||||
Leverage Ratio | 1.20 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
70.60 | ||||
-32.00 | ||||
-27.30 | ||||
-3 870.40 | ||||
-32.14 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
187.78M | ||||
3.79 | ||||
295.53 | ||||
- |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q01 2023 | -0.34 | -0.19 | 44.12 |
Q04 2022 | -0.23 | 0.01 | 104.35 |
Q03 2022 | -0.47 | -0.34 | 27.66 |
Q02 2022 | -0.57 | -0.47 | 17.54 |
Q01 2022 | -0.69 | -0.50 | 27.54 |
Q04 2021 | -0.36 | -0.34 | 5.56 |
Q03 2021 | -0.46 | -0.38 | 17.39 |
Q02 2021 | -0.51 | -0.59 | -15.69 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
6/2023 QR | -0.12 | 7.69 | Positive |
9/2023 QR | -0.10 | 23.08 | Positive |
12/2023 FY | -0.40 | 31.03 | Positive |
12/2024 FY | -0.04 | 73.33 | Positive |
Next Report Date | - |
Estimated EPS Next Report | -0.34 |
Estimates Count | 5 |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 94.24K |
Shares Outstanding | 50.38K |
Shares Float | 49.80M |
Trades Count | 2.90K |
Dollar Volume | 4.80M |
Avg. Volume | 552.09K |
Avg. Weekly Volume | 513.82K |
Avg. Monthly Volume | 549.39K |
Avg. Quarterly Volume | 593.07K |
Axonics Modulation Technologies Inc. (NASDAQ: AXNX) stock closed at 50.85 per share at the end of the most recent trading day (a 3.42% change compared to the prior day closing price) with a volume of 628.71K shares and market capitalization of 2.58B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 302 people. Axonics Modulation Technologies Inc. CEO is Raymond Wayne Cohen.
The one-year performance of Axonics Modulation Technologies Inc. stock is -12.27%, while year-to-date (YTD) performance is -18.68%. AXNX stock has a five-year performance of %. Its 52-week range is between 46.57 and 79.915, which gives AXNX stock a 52-week price range ratio of 13.87%
Axonics Modulation Technologies Inc. currently has a PE ratio of -36.40, a price-to-book (PB) ratio of 5.38, a price-to-sale (PS) ratio of 14.51, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -13.64%, a ROC of -14.09% and a ROE of -15.66%. The company’s profit margin is -32.14%, its EBITDA margin is -27.30%, and its revenue ttm is $187.78 Million , which makes it $3.79 revenue per share.
Of the last four earnings reports from Axonics Modulation Technologies Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.34 for the next earnings report. Axonics Modulation Technologies Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Axonics Modulation Technologies Inc. is Moderate Buy (1.55), with a target price of $82.67, which is +61.99% compared to the current price. The earnings rating for Axonics Modulation Technologies Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Axonics Modulation Technologies Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Axonics Modulation Technologies Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 9.41, ATR14 : 1.98, CCI20 : -29.58, Chaikin Money Flow : -0.16, MACD : -1.61, Money Flow Index : 25.96, ROC : 1.03, RSI : 47.23, STOCH (14,3) : 51.58, STOCH RSI : 1.00, UO : 52.49, Williams %R : -48.42), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Axonics Modulation Technologies Inc. in the last 12-months were: Alfred J. Ford (Option Excercise at a value of $486 817), Alfred J. Ford (Sold 36 015 shares of value $2 391 415 ), Cohen Raymond (Sold 44 000 shares of value $3 099 351 ), Danny L. Dearen (Option Excercise at a value of $1 810 769), Danny L. Dearen (Sold 225 314 shares of value $15 039 386 ), Esteban Lopez (Sold 2 000 shares of value $134 840 ), Jane E. Kiernan (Sold 5 250 shares of value $315 000 ), John Woock (Option Excercise at a value of $550 904), John Woock (Sold 45 215 shares of value $3 159 579 ), Karen Noblett (Option Excercise at a value of $623 335), Karen Noblett (Sold 32 483 shares of value $2 538 799 ), Kiernan Jane (Sold 5 250 shares of value $315 000 ), Raymond Wayne Cohen (Sold 84 736 shares of value $5 785 326 ), Rinda Sama (Sold 36 415 shares of value $2 241 166 ), Sama Rinda (Sold 0 shares of value $-576 872 ), Sama Rinda (Sold 70 265 shares of value $4 596 018 ), Woock John (Sold 0 shares of value $-12 225 ), Woock John (Sold 22 500 shares of value $1 592 771 )
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Strong Buy | Strong Buy | Moderate Buy |
Axonics Modulation Technologies Inc is a United stated based medical technology company. It focuses on the design, development, and commercialization of innovative and minimally invasive sacral neuromodulation (SNM) solutions. SNM therapy is primarily used to treat patients with overactive bladder, fecal incontinence, and urinary retention. The company has designed and developed the r-SNM System, which delivers mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of overactive bladder and fecal incontinence.
CEO: Raymond Wayne Cohen
Telephone: +1 949 396-6322
Address: 26 Technology Drive, Irvine 92618, CA, US
Number of employees: 302
Mon, 01 May 2023 17:15 GMT Axonics Modulation Technologies (AXNX) Receives a Buy from Mizuho Securities
- TipRanks. All rights reserved.Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Copyright © 2023. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer.
General partner of Finscreener is SLOVAKODATA, a.s.
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.